Brickell Biotech to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on November 9, 2021

Rhea-AI Summary

Brickell Biotech, Inc. (Nasdaq: BBI) announced its plans to report financial results for the third quarter ended September 30, 2021, on November 9, 2021. The conference call will be held at 4:30 PM ET, where management will discuss financial highlights and recent developments. Brickell focuses on developing innovative therapeutics for dermatologic and autoimmune diseases, boasting a late-stage program for hyperhidrosis. The company leverages its experienced executive team to advance its product pipeline aimed at underserved chronic diseases.

Positive

• Late-stage program for hyperhidrosis could be a significant revenue driver.
• Experienced management team with a history of successful product launches.

Negative

• None.

BOULDER, Colo., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases, announced today that it will report its financial results for the third quarter, ended September 30, 2021. Brickell’s management will host a conference call and webcast at 4:30 pm ET on Tuesday, November 9^th to discuss the financial results and recent corporate highlights.

To access the call, please dial 877-705-6003 in the U.S. or 201-493-6725 outside the U.S. and provide the conference ID number: 13723603. To access the live webcast, please go to the Investors section of Brickell’s website at https://ir.brickellbio.com/events-presentations. Following the live webcast, an archived version of the call will be available on the website.

About Brickell

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases. Brickell’s pipeline combines a potential best-in-class, late-stage program for hyperhidrosis with a novel, cutting-edge platform and development stage candidates with broad potential in autoimmune and neuroinflammatory disorders. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis^®, Taltz^®, Gemzar^®, Prozac^®, Cymbalta^® and Juvederm^®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative pharmaceutical products that Brickell believes can meaningfully benefit patients who are suffering from chronic debilitating diseases that are underserved by available therapies. For more information, visit https://www.brickellbio.com.

Brickell Investor Contact:
Dan Ferry
LifeSci Advisors
(617) 430-7576
daniel@lifesciadvisors.com

FAQ

What are Brickell Biotech's financial results for Q3 2021?

Brickell Biotech will announce its financial results for the third quarter of 2021 on November 9, 2021.

When is the conference call to discuss Brickell's Q3 results?

The conference call is scheduled for November 9, 2021, at 4:30 PM ET.

What is the focus of Brickell Biotech's product development?

Brickell Biotech focuses on developing therapeutics for dermatologic and autoimmune diseases.

What is the significance of Brickell's late-stage program?

The late-stage program for hyperhidrosis could significantly impact Brickell's revenue and market position.

How can I access the Brickell Biotech conference call?

You can access the call by dialing 877-705-6003 in the U.S. or 201-493-6725 internationally, using conference ID 13723603.